These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 19634921)

  • 1. The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.
    Katsiki N; Georgiadou E; Hatzitolios AI
    Drugs; 2009 Jul; 69(11):1417-31. PubMed ID: 19634921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
    Zhao H; Xing C; Zhang J; He B
    Reprod Health; 2021 Aug; 18(1):171. PubMed ID: 34407851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update.
    Katsiki N; Hatzitolios AI
    Curr Opin Obstet Gynecol; 2010 Dec; 22(6):466-76. PubMed ID: 20724929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
    Elkind-Hirsch KE
    Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-sensitizing agents in polycystic ovary syndrome.
    Pasquali R; Gambineri A
    Eur J Endocrinol; 2006 Jun; 154(6):763-75. PubMed ID: 16728533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin effects on clomifene-induced ovulation in the polycystic ovary syndrome.
    Ben Ayed B; Dammak dit Mlik S; Ben Arab H; Trabelssi H; Chahtour H; Mathlouthi N; Dhuib M; Kassis M; Saiidane D; Trabelssi K; Guermazi M
    Tunis Med; 2009 Jan; 87(1):43-9. PubMed ID: 19522426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of insulin-sensitizing agents in patients with polycystic ovary syndrome.
    Bloomgarden ZT; Futterweit W; Poretsky L
    Endocr Pract; 2001; 7(4):279-86. PubMed ID: 11497481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance in polycystic ovarian disease.
    Bhatia V
    South Med J; 2005 Sep; 98(9):903-10; quiz 911-2, 923. PubMed ID: 16217983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin sensitizers in adolescents with polycystic ovary syndrome.
    LE TN; Wickham EP; Nestler JE
    Minerva Pediatr; 2017 Oct; 69(5):434-443. PubMed ID: 28497664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects.
    Nardo LG; Rai R
    Gynecol Endocrinol; 2001 Oct; 15(5):373-80. PubMed ID: 11727360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of PCOS with metformin and other insulin-sensitizing agents.
    Seli E; Duleba AJ
    Curr Diab Rep; 2004 Feb; 4(1):69-75. PubMed ID: 14764283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin sensitizers in polycystic ovary syndrome.
    Pasquali R; Gambineri A
    Front Horm Res; 2013; 40():83-102. PubMed ID: 24002407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical inquiries. Do insulin-sensitizing drugs increase ovulation rates for women with PCOS?
    Andy C; Flake D; French L
    J Fam Pract; 2005 Feb; 54(2):156, 159-60. PubMed ID: 15689292
    [No Abstract]   [Full Text] [Related]  

  • 14. Insulin sensitizers and antiandrogens in the treatment of polycystic ovary syndrome.
    Diamanti-Kandarakis E; Zapanti E
    Ann N Y Acad Sci; 2000; 900():203-12. PubMed ID: 10818407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Polycystic ovary syndrome: treatment with insulin-sensitizing agents].
    Laboureau-Soares Barbosa S; Rodien P; Rohmer V
    Ann Endocrinol (Paris); 2002 Feb; 63(1):31-5. PubMed ID: 11937980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
    Unlühizarci K; Keleştimur F; Bayram F; Sahin Y; Tutuş A
    Clin Endocrinol (Oxf); 1999 Aug; 51(2):231-6. PubMed ID: 10468995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
    Moghetti P; Castello R; Negri C; Tosi F; Perrone F; Caputo M; Zanolin E; Muggeo M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):139-46. PubMed ID: 10634377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
    De Leo V; Musacchio MC; Palermo V; Di Sabatino A; Morgante G; Petraglia F
    Drugs Today (Barc); 2009 Oct; 45(10):763-75. PubMed ID: 20069140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome?
    Cheang KI; Nestler JE
    Reprod Biomed Online; 2004 Apr; 8(4):440-7. PubMed ID: 15149568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-sensitisers in the treatment of polycystic ovary syndrome.
    Teede HJ; Meyer C; Norman RJ
    Expert Opin Pharmacother; 2005 Nov; 6(14):2419-27. PubMed ID: 16259573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.